Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Nov

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Melanoma Cancer Cluster Found in Parts of Pennsylvania

FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC

Patient Immune System Characteristics and Long-Term Remission From CAR T-Cell Therapy in Multiple Myeloma

Vorasidenib in IDH1/2-Mutant Low-Grade Glioma

New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets